ERNA

Eterna Therapeutics Inc

ERNA, USA

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

https://www.ernexatx.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ERNA
stock
ERNA

Retail Trends: Can ERNA reach all time highs this year - Inflation Watch & AI Powered Trade Plan Recommendations bollywoodhelpline.com

Read more →
ERNA
stock
ERNA

Can SNTI stock double in the next year - Forecast Cut & Community Trade Idea Sharing bollywoodhelpline.com

Read more →

Showing 2 of 10

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

0.02

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

2.74

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-34.73 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-20.09 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Low

0.73

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 1.05% of the total shares of Eterna Therapeutics Inc

1.

Geode Capital Management, LLC

(0.2617%)

since

2025/06/30

2.

CI Private Wealth LLC

(0.2284%)

since

2025/06/30

3.

Fidelity Extended Market Index

(0.1695%)

since

2025/07/31

4.

Vanguard Institutional Extnd Mkt Idx Tr

(0.1366%)

since

2025/07/31

5.

Sippican Capital Adivsors

(0.1304%)

since

2025/06/30

6.

Fidelity Series Total Market Index

(0.0416%)

since

2025/07/31

7.

Spartan Extended Market Index Pool F

(0.0408%)

since

2025/07/31

8.

BlackRock Inc

(0.0107%)

since

2025/06/30

9.

Spartan Total Market Index Pool G

(0.0079%)

since

2025/07/31

10.

Morgan Stanley - Brokerage Accounts

(0.0072%)

since

2025/06/30

11.

UBS Group AG

(0.0071%)

since

2025/06/30

12.

Fidelity Total Market Index

(0.0018%)

since

2025/07/31

13.

Genworth Financial Wealth Mgmt Inc

(0.0017%)

since

2025/06/30

14.

NT Ext Equity Mkt Idx Fd - NL

(0.001%)

since

2025/06/30

15.

NT Ext Equity Mkt Idx Fd - L

(0.001%)

since

2025/06/30

16.

Northern Trust Extended Eq Market Idx

(0.001%)

since

2025/06/30

17.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0008%)

since

2025/06/30

18.

State St US Extended Mkt Indx NL Cl C

(0.0007%)

since

2025/08/31

19.

Bank of America Corp

(0.0003%)

since

2025/06/30

20.

SSgA U.S. Total Market Index Strategy

(0.0003%)

since

2025/03/31

21.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0003%)

since

2025/06/30

22.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0002%)

since

2024/12/31

23.

BNYM Mellon SL Market Completion UC1

(0.0002%)

since

2025/06/30

24.

BNP Paribas Arbitrage, SA

(0.0001%)

since

2025/06/30

25.

A. Montag & Associates Inc

(0.0001%)

since

2025/06/30

26.

Northern Trust Wilshire 5000

(0.0001%)

since

2025/06/30

27.

State St US Ttl Mkt Indx NL Cl A

(0.0001%)

since

2025/08/31

28.

Activest Wealth Management

(0%)

since

2025/06/30

29.

FMR Inc

(0%)

since

2025/03/31

30.

Goldman Sachs Group Inc

(0%)

since

2025/03/31

32.

JustInvest LLC

(0%)

since

2025/06/30

33.

Citadel Advisors Llc

(0%)

since

2025/06/30

34.

Millennium Management LLC

(0%)

since

2025/03/31

36.

one8zero8, LLC

(0%)

since

2025/06/30

37.

SBI Securities Co Ltd

(0%)

since

2025/06/30

38.

Guggenheim Active Allocation Fund

(0%)

since

2025/05/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-06-30

EPS Actual

-0.61

EPS Estimate

0

EPS Difference

-0.61

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(6)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(2.5)
Value
Undervalued(6.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.